De novo generation of the NPM-ALK fusion recapitulates the pleiotropic phenotypes of ALK+ ALCL pathogenesis and reveals the ROR2 receptor as target for tumor cells.

Loélia BabinAlice DarchenElie RobertZakia AidRosalie BorryClaire SoudaisMarion PiganeauAnne De CianCarine GiovannangeliOlivia BawaCharlotte RigaudJean-Yves ScoazecLucile CouronnéLayla VeleanuAgata CieslakVahid AsnafiDavid SibonLaurence LamantFabienne MeggettoThomas MercherErika Brunet

Published in: Molecular cancer (2022)

In this study, ab initio modeling of the ALK+ ALCL chromosomal translocation in mature T lymphocytes enabled the identification of new therapeutic targets. As ROR2 targeting approaches for other cancers are under development (including lung and ovarian tumors), our findings suggest that ALK+ ALCL cases with resistance to current therapies may also benefit from ROR2 targeting strategies.

Keyphrases

advanced non small cell lung cancer
cancer therapy
epidermal growth factor receptor
gene expression
copy number
drug delivery
tyrosine kinase